News About Compounded Tirzepatide: What Regulators Have Published

By What Peptides Editorial Team · Updated 2026-09-14 · Part of Peptide Research, Industry Updates & Practical Guides

Compounded tirzepatide is a regulatory topic rather than a product category. Tirzepatide is a 39 residue peptide that acts at both the glucose dependent insulinotropic polypeptide and the glucagon like peptide 1 receptors, and it is a prescription medicine in the jurisdictions where it is approved. Compounding is a separate legal activity: the preparation of a medicine by a pharmacist for an identified individual, usually to address a need an approved product does not meet, such as an allergy to an excipient or an unavailable presentation. This page reports what regulators have published about that distinction and how a reader can check a status. It gives no patient guidance.

The distinction is worth stating carefully, because one word covers two very different things. An approved medicine has been assessed by a regulator for quality, safety and efficacy, and it carries a licensed label, a marketing authorisation holder and a defined manufacturing site. A compounded preparation has not been assessed in that way: it is not an approved product, it holds no marketing authorisation, and no regulator has verified its equivalence. Where regulators have published on this, the wording is consistent. See peptide research and industry updates for more in this cluster, and how this site approaches public documentation for the verification habit.

What compounding means in law and in practice

Compounding sits inside pharmacy practice and is regulated at the level of the individual preparation rather than the product. In the United States two broad categories are described: preparations made by a licensed pharmacist or physician for an identified individual patient, and preparations made in larger quantities by facilities registered as outsourcing facilities under a separate section of the drug law. The two are treated differently, and the section of law that applies determines what the regulator expects. Other jurisdictions use different frameworks entirely, and several restrict compounding of a medicine that is already commercially available.

Two further terms matter. A salt form is a specific chemical entity, and the name of the salt appears in the approval. Where a compounded preparation uses a different salt, such as a citrate or acetate form rather than the approved entity, that preparation is not the approved product, and regulators have published statements on that point. An active pharmaceutical ingredient used in compounding is expected to come from a registered source and to comply with the applicable pharmacopoeial standard, and it is not the same thing as a material sold as a research chemical. That boundary is set out in what the research use only label means.

What regulators have published and where the wording sits

Regulator output on this topic appears in several document types, and knowing which one you are reading matters. A safety communication or drug safety update is a short public statement, usually about a specific risk. A guidance for industry states how the regulator intends to exercise its enforcement discretion, and it is not itself a rule. A warning letter is an enforcement document addressed to a named party. A question and answer page is the most reader-facing of the four and is usually the clearest starting point. Each document is dated, and the date matters because the underlying supply situation has shifted more than once.

In the United States, the Food and Drug Administration has published on the difference between an approved product and a compounded version, on the use of salt forms that are not the approved entity, and on the conditions under which compounding of a commercially available medicine is permitted. The agency also maintains a list of bulk drug substances that may be used in compounding, and whether a substance appears on that list is a checkable fact. In the European Union, the European Medicines Agency assesses centrally authorised products, while compounding is largely a national matter. Neither arrangement is static, which is why the register rather than a news summary is the source to use.

• Check the publication date first; supply status and enforcement positions have both changed repeatedly.
• Distinguish guidance from rule: a guidance states intent, a regulation states obligation.
• Look for the named entity, since a warning letter applies to the party it addresses.
• Confirm the salt form against the approval rather than against a supplier listing.
• Read the national register entry, which is the authoritative statement of status.

How to verify a status on an official register

Verification is a short procedure with a fixed sequence. In the United States, the Orange Book lists approved drug products with therapeutic equivalence evaluations, and DailyMed carries the current label text supplied by the manufacturer. State boards of pharmacy publish licence records for pharmacies and for outsourcing facilities. In the European Union, the European Medicines Agency publishes a medicines database with product information for centrally authorised products, and national regulators maintain their own registers. In the United Kingdom, the national medicines regulator maintains its own listings. Each of these is searchable by product name or by active substance.

The check itself has three steps. Confirm that the product name appears on the register, and read the marketing authorisation holder. Confirm the strength and the presentation, since an approval covers a defined set of presentations rather than a substance in general. Then confirm the manufacturer or the dispensing pharmacy against the licence record for that jurisdiction. If a seller cannot be found on any register, that is a fact about the listing rather than an interpretation, and it is the most informative thing a reader can establish. Our page on how tirzepatide brand names are recorded walks through the naming side of the same check.

This page is part of the Peptide Research, Industry Updates & Practical Guides guide.